LBF20207PG41: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=15(R)-PGD2 is reported to have potent agonistic effect to the DP2 receptor 5 time higher than PGD2.[[Reference:Giles_H:Leff_P:Bolofo_ML:Kelly_MG:Robertson_AD:,Br. J. Pharmacol.,1989,96,291|{{RelationTable/GetFirstAuthor|Reference:Giles_H:Leff_P:Bolofo_ML:Kelly_MG:Robertson_AD:,Br. J. Pharmacol.,1989,96,291}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Revision as of 21:00, 6 January 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1772 |
| LipidMaps | LMFA03010102 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG41 |
| 15 (R) -Prostaglandin D2 | |
|---|---|
| |
| Structural Information | |
| 9a,15R-dihydroxy-11-oxo-prosta-5E,13E-dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC |
| Physicochemical Information | |
| 15(R)-PGD2 is reported to have potent agonistic effect to the DP2 receptor 5 time higher than PGD2. Giles_H et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
